RT Journal Article
SR Electronic
T1 Hippocampal subfield volume in relation to cerebrospinal fluid Amyloid-ß in early Alzheimer’s disease: Diagnostic Utility of 7T MRI
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.24.24315913
DO 10.1101/2024.10.24.24315913
A1 Adeyemi, Oluwatobi F
A1 Gowland, Penny
A1 Bowtell, Richard
A1 Mougin, Olivier
A1 Hosseini, Akram A.
YR 2024
UL http://medrxiv.org/content/early/2024/10/24/2024.10.24.24315913.abstract
AB INTRODUCTION: Alzheimer's disease (AD) is a neurodegenerative condition characterised by amyloid plaque accumulation and neurofibrillary tangles. Early detection is essential for effective intervention, but current diagnostic methods that enable early diagnosis in clinical practice rely on invasive or costly biomarker scanning. This study aimed to explore the utility of 7T MRI in assessing hippocampal subfield volumes and their correlation with cerebrospinal fluid (CSF) biomarkers in prodromal AD. METHODS: Fifty-six participants, including AD patients and healthy controls, underwent 7T MRI scanning. Automated segmentation delineated hippocampal subfield volumes, with subsequent normalization to whole brain volume. RESULTS: Significant differences in hippocampal and subfield volumes were observed in prodromal AD patients, even when they did not exhibit high MTA scores on 3T MRI or show any whole brain volume loss. Additionally, the volume of the entorhinal cortex (ERC) correlated significantly with CSF amyloid-beta; levels, suggesting ERC's potential as a proxy CSF amyloid-beta measurement. Conversely, no significant associations were found between CSF 181-phospho-tau or total tau levels and any hippocampal subfield volumes. DISCUSSION: These findings show the potential use of 7T MRI, particularly in ERC assessment, as a biomarker for early AD identification. Further validation studies are warranted to confirm these results and elucidate the relationship of ERC volume with CSF biomarkers.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocolshttps://clinicaltrials.gov/study/NCT04992975?cond=NCT04992975&rank=1Funding StatementThis study is funded by the Medical Research Council, UK (grant MR/T005580/1) through Clinical Academic Partnership Award to AAH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project received favourable opinion from the East Midlands-Nottingham 2 research Ethics committee (reference: 20/EM/0023) and the UK Health Research Authority (IRAS:276174). The committee is constituted in accordance with the Governance Arrangement for research Ethics committee and complies fully with the Standard Operating Procedures for Research Ethics Committee in the UKI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData is Available on request